Helalink Pharmaceutical

Helalink is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the discovery and development of innovative small molecule therapeutics for oncology and metabolic diseases. The company focuses on targeting the MAPK/ERK signaling pathway, which is frequently dysregulated in various cancers. Its lead product candidate, tunmetinib (HL-085), is a potent and selective MEK1/2 inhibitor currently in late-stage clinical development for NRAS-mutant melanoma. Additionally, Helalink is advancing HL-007, a BRAF inhibitor, both as a monotherapy and in combination with its MEK inhibitor. By leveraging its internal R&D platform, the company aims to provide effective precision medicines to address significant unmet needs in the global pharmaceutical market.